Teva wins battle with Pfizer over Viagra patent

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

Teva wins battle with Pfizer over Viagra patent

viagra2-1-45.jpg

The Supreme Court of Canada on Thursday said that Pfizer’s blockbuster patent on the erectile dysfunction drug Viagra is invalid, reversing a Federal Court ruling that blocked Teva's application to market generic Viagra under the Patented Medicines (Notice of Compliance) Act (PM[NOC])

The decision is interesting in that the Supreme Court took the step of finding the patent invalid, rather than simply allowing the Canadian Minister of Health to grant the notice of compliance, said Sean Jackson of IP Osgoode.

viagra2-1-250.jpg

It has also clarified the Canadian disclosure requirement. “Sufficiency of disclosure lies at the very heart of the patent system, so adequate disclosure in the specification is a precondition for the granting of a patent,” said the judgment. In this respect, the Court found Pfizer’s patent lacking. The panel explained: “Although the patent includes the statement that ‘one of the especially preferred compounds induces penile erection in impotent males’, the patent application does not disclose that the compound that works is sildenafil, that it is found in Claim 7, or that the remaining compounds had not been found to be effective in treating ED.”

Pfizer’s patent was due to expire in 2014. Teva said its generic version of the drug will “result in millions in savings to consumers”.

more from across site and SHARED ros bottom lb

More from across our site

The firm has brought in former Weil IP leaders Doug Lumish and Jeff Homrig as it looks to deepen its patent, trade secrets and ITC bench
Bird & Bird helps GSK score a major injunction as the battle to become the UPC’s busiest division tightens, and overall filings reach a new monthly high
CEO Annette Bach explains how the Danish IP consultancy plans to build on its 65% profit growth while keeping external investment off the table for now
Belgian attorneys have revived fax systems to protect clients’ filing rights, while uncertainty over exposed patent data has left firms struggling to answer questions about the breach
In his first interview since leaving Weil Gotshal & Manges, Chris Henry explains why he returned to Latham and how he plans to bolster its tech disputes offering
As GTA VI underlines the extraordinary value of gaming franchises, lawyers at Clifford Chance say investors need to know the IP behind their next deal can deliver the growth they are paying for
As ‘big law’ invests in IP litigation, trial firms are emerging as a valuable source of seasoned courtroom talent
Six hires across the IP spectrum reflect Orrick’s efforts to better serve tech clients across the IP lifecycle
David Stone, partner at White & Case, argues that the government’s planned reforms will modernise and futureproof UK design law, but leave two of the thorniest problems unresolved
Max Scott will join the firm’s IP transactions group in California, becoming the latest Weil IP partner to secure their future
Gift this article